Consistent with HER2 levels detected in the whole cell lysates by WB, HER2 levels determined by flow cytometry were lower on the cancer cell surface with co-treatment of trastuzumab and PBMCs than that on control cells as indicated by the decreased MFI in the flow histograms (Figure 1B). The gene discussed is ERBB2; the disease is cancer.